Research programme: peptide-radioisotope therapeutics - Genentech/PeptiDream
Latest Information Update: 03 Nov 2023
At a glance
- Originator PeptiDream
- Developer Genentech
- Class Macrocyclic compounds; Peptide drug conjugates; Radioisotopes
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified